U.S. pharma large copyright scrapped two experimental weight loss tablets final calendar year—a at the time-every day pill, lotiglipron, resulting from elevated liver enzymes as well as a twice-everyday capsule, danuglipron, on account of solid Uncomfortable side effects—but CEO Albert Bourla has reported the company is decided to “Participat